Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC Meeting Abstract

  

Authors:	Fujiwara, Y.; Burns, T. F.; Dragnev, K. H.; Murciano-Goroff, Y. R.; Lee, D. H.; Hollebecque, A.; Koyama, T.; Cassier, P. A.; Italiano, A.; Heist, R. S.; Han, J. Y.; Deming, D. A.; Spira, A. I.; Sabari, J. K.; Chisamore, M. J.; Fink, Aaron Alan; Chen, A.; Willard, M. D.; Oxnard, G. R.; Ammakkanavar, N. R.
Abstract Title:	Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
Meeting Title:	2024 ASCO Breakthrough: A Global Summit for Oncology Innovators
Journal Title:	Journal of Clinical Oncology
Volume:	42
Issue:	23 Suppl.
Meeting Dates:	2024 Aug 8-10
Meeting Location:	Yokohama, Japan
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2024-08-10
Start Page:	195
Language:	English
DOI:	10.1200/JCO.2024.42.23_suppl.195
PROVIDER:	EBSCOhost
PROVIDER:	cinahl plus with full text
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=rzh&AN=178967488&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting abstract: 195 -- Also held virtually -- Source: CINAHL Plus with Full Text

https://synapse.mskcc.org/synapse/works/has_related_data_chk/218571